- Home
- DAVE vs ELVN Comparison
DAVE vs ELVN Comparison
Compare DAVE & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVE
- ELVN
- Stock Information
- Founded
- DAVE 2017
- ELVN 2016
- Country
- DAVE United States
- ELVN United States
- Employees
- DAVE N/A
- ELVN N/A
- Industry
- DAVE Retail: Computer Software & Peripheral Equipment
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- DAVE Technology
- ELVN Health Care
- Exchange
- DAVE Nasdaq
- ELVN Nasdaq
- Market Cap
- DAVE 1.1B
- ELVN 927.8M
- IPO Year
- DAVE N/A
- ELVN 2020
- Fundamental
- Price
- DAVE $200.82
- ELVN $17.77
- Analyst Decision
- DAVE Strong Buy
- ELVN Strong Buy
- Analyst Count
- DAVE 7
- ELVN 4
- Target Price
- DAVE $169.71
- ELVN $37.25
- AVG Volume (30 Days)
- DAVE 618.3K
- ELVN 361.5K
- Earning Date
- DAVE 05-08-2025
- ELVN 05-14-2025
- Dividend Yield
- DAVE N/A
- ELVN N/A
- EPS Growth
- DAVE N/A
- ELVN N/A
- EPS
- DAVE 3.70
- ELVN N/A
- Revenue
- DAVE $381,425,000.00
- ELVN N/A
- Revenue This Year
- DAVE $34.79
- ELVN N/A
- Revenue Next Year
- DAVE $16.48
- ELVN N/A
- P/E Ratio
- DAVE $54.28
- ELVN N/A
- Revenue Growth
- DAVE 39.31
- ELVN N/A
- 52 Week Low
- DAVE $28.31
- ELVN $13.30
- 52 Week High
- DAVE $220.34
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- DAVE 73.41
- ELVN 49.54
- Support Level
- DAVE $190.41
- ELVN $15.81
- Resistance Level
- DAVE $220.34
- ELVN $17.54
- Average True Range (ATR)
- DAVE 9.81
- ELVN 1.30
- MACD
- DAVE 0.76
- ELVN -0.04
- Stochastic Oscillator
- DAVE 62.70
- ELVN 38.06
About DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.